Global Rheumatology Treatment Drugs List in 2022
Rheumatoid arthritis (RA) is a chronic, progressive, multiple, invasive autoimmune disease characterized by joint synovitis and extra-articular lesions. There is no obvious regional and age difference in the incidence, but there are obvious family genetic characteristics. In recent years, the incidence of rheumatic diseases has increased significantly and the mortality rate has been high. Clinical studies have found that about 30% of people worldwide suffer from varying degrees of rheumatic diseases, with a standard mortality rate of 1.28%-2.98%, and the resulting complications can lead to low joint function, which seriously affects patients. The quality of life brings a heavy economic burden to society. Therefore, effective treatment of RA has become the focus of the global pharmaceutical industry. According to Evaluate Pharma, RA treatments rank second in the global pharmaceutical market, second only to anti-cancer drugs (2016 sales of $93.7 billion). In 2016, sales of global anti-rheumatic drugs reached $53.3 billion, an increase of nearly $4.5 billion compared to $48.8 billion in 2015. According to the Evaluate Pharma report, global anti-rheumatic drug sales will reach $54.5 billion in 2022. First, 2016-2022 sales company TOP10 The best-selling anti-rheumatic drug is Aberdeen's Xiu Mei Le. The drug's global sales in 2016 exceeded US$16 billion, accounting for 30.2% of the market. According to Evaluate Pharma's report, it will still be in 2022. Take the first place in the market. Due to the popularity of Otezla, Celegen has also maintained its leading position; Otezla's sales in 2016 exceeded $1 billion, according to Evaluate Pharma's report, its global sales will reach 36.73 in 2022. Billion dollars, compound growth rate (CAGR) as high as 24%. Second, 2022 global sales of RA treatment drugs TOP 5 According to the Evaluate Pharma report, the top five global anti-rheumatic drugs in 2022 were: TOP1 adalimumab Humira, global sales in 2015 was 15.601 billion US dollars, compound growth rate -1%; TOP2 Enasi Enbrel, global sales in 2005 was 5.276 billion US dollars, compound growth rate was -9%; TOP3 Apster Otezla, global sales in 2022 was 3.673 billion US dollars, compound growth rate was +24%; TOP4 Golimumab Simponi, global sales in 2005 was $3.582 billion, with a compound growth rate of +6%; TOP5 Infliximab Remicade, global sales in 2012 was $2.742 billion, a compound growth rate of -16%. 1. Humira [English name] Humira [Chinese trade name] Xiu Mei Le [Chinese drug name] adalimumab [Formulation and specifications] Injection, 40mg/0.8ml [Manufacturer Name] AbbVie / Eisai Humira was approved by the US Food and Drug Administration (FDA) on December 31, 2002. The approved dosage form is an injection with a specification of 40 mg/0.8 ml; this drug is a fully humanized, highly specific binding to TNF. Monoclonal antibodies can be used to treat RA, psoriatic arthritis and ankylosing spondylitis (AS), as well as inflammatory bowel disease. Humira has been approved by the State Food and Drug Administration (CFDA) for two indications for the treatment of RA and AS. As can be seen from the sales data, Abbimie (AbbVie) has been the world's sales champion for nearly three years, and sales are growing. Since its patents will expire in 2018, sales may be impacted by generics, and the compound growth rate will be reduced. According to the Evaluate Pharma report, sales in 2012 were $15.901 billion. As can be seen from the PDB database, adalimumab has grown at a faster rate since its domestic listing in 2010. In 2013, sales peaked and sample hospital sales reached 24.6 million yuan. After 2013, sales in the domestic market declined slightly. In 2016, the sales of sample hospitals fell to 19.44 million yuan. 2, Enbrel [English trade name] Enbrel [Chinese trade name] Enli [Chinese drug name] etanercept [Formulation and specifications] Injection, 25mg/vial & 50mg/ml [manufacturer name] Amgen/Pfizer/Takeda Enbrel was approved by the FDA on November 2, 1998, and approved for injections, 25 mg/vial and 50 mg/ml, for the treatment of RA and AS bio-DMARD drugs (anti-rheumatic drugs for improved disease). Currently, etanercept has been approved by the CFDA for the treatment of moderate to severe active RA and severely active AS in adult patients. As can be seen from the sales data, Amgen & Pfizer's global sales have been relatively stable in the past three years. According to the Evaluate Pharma report, sales will fall sharply in 2022, with a compound growth rate of -9%, which may be affected by it. The impact of generic drugs is related. In the past seven years of domestic market sales of etanercept: As can be seen from the PDB database, etanercept reached the peak in domestic market sales in 2013, and sample hospital sales reached 28.24 million yuan. After 2013, sales declined slightly. In 2016, the sample hospital sales were 2015 million yuan, which was slightly better than the adalimumab. 3, Otezla [English name] Otezla [Chinese drug name] Apster [Formulation and specifications] tablets, 10mg/20mg/30mg [Manufacturer Name] Celegen Otezla was approved by the FDA on March 21, 2014. The approved dosage form is tablets, 10mg, 20mg and 30mg. This drug is an oral, selective phosphodiesterase 4 (PDE 4) inhibitor for For adults with moderate to severe plaque psoriasis, the drug is the first and only FDA-approved drug for plaque-type psoriasis rheumatoid arthritis. Currently, the drug has not yet entered the Chinese market. Global sales of Celegen in the past three years: Otezla's second-year sales reached $472 million. In 2016, its global sales reached $1.017 billion, an annual growth rate of 115%. According to Evaluate Pharma's report, sales in 2022 will exceed $3 billion. 4, Simponi [English name] Simponi [Chinese drug name] Golimumab [Formulation and specifications] Injection, 50mg/vial [name of manufacturer] Johnson & Johnson / Merck Simponi was approved by the FDA on April 24, 2009. The approved dosage form is an injection with a specification of 50 mg/vial. Golimumab is a fully human monoclonal antibody injected subcutaneously once a month for the treatment of moderate to Severity of RA, psoriatic arthritis, and active AS. On July 18, 2013, the FDA approved the administration of Simponi Aria for the treatment of moderate to severe RA. Currently, the drug has not yet entered the Chinese market. 5, Remicade [English name] Remicade [Chinese drug name] Infliximab [Chinese trade name] class gram [Formulation and specifications] Injection, 100mg/vial [name of manufacturer] Johnson & Johnson / MSD / Mitsubishi Remicade was approved by the US FDA on August 24, 1998. The approved dosage form is an injectable, 100 mg/vial, for the treatment of RA, moderate to severe active Crohn's disease, fistula Crohn's disease, and AS biologics. . Infliximab (Johnson & MSD) sales have declined in the past three years and may be related to the approval of Pfizer's biosimilar drug Inflectra (infliximab - dyyb) injection, clinical data show that Infliximab -dyyb and Remicade Efficacy equivalence. Infliximab was approved by CFDA for import in 2006, ahead of the drugs adalimumab and etanercept. From the PDB database, infliximab has been increasing domestic sales for nearly seven years, 2016 sample Hospital sales reached 121 million yuan, about six times the sales of adalimumab and etanercept. Third, the most potential RA treatment in 2022 According to the Evaluate Pharma report, the five most potential research drugs in the world in 2022 are Abbott's ABT-494; Johnson & Johnson's Sirukumab; Flexion's Zilretta; Amgen's ABP-710 and Gilead and Galapagos The company's Filgotinib, which accounts for about 6% of the market share of RA treatments. Tetanus Toxoid Vaccine,Toxoid Vaccine,Hep B Immune Globulin,Immunoglobulin Injections FOSHAN PHARMA CO., LTD. , https://www.fspharmamedicine.com